Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fast Forward And Myelin Repair Foundation: Two Routes To New MS Drugs

This article was originally published in Start Up

Executive Summary

Despite the availability of new oral medicines, larger advances in MS remain elusive, especially for those with advanced MS. Two nonprofit groups, the National MS Society’s Fast Forward venture arm and the Myelin Repair Foundation, are thinking creatively in different ways – but both spending millions of dollars – to make those breakthroughs come sooner.

You may also be interested in...



MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?

Several new drugs for multiple sclerosis could launch within the next two years, but amid escalating drug costs, payors are taking a harder look at the therapeutic category. New drugs will face increasing reimbursement hurdles, as payors implement the first prior authorization and step therapy protocols and look for ways to implement further cost reductions.

A More Integrated Approach To Looking At GPCR Signaling

G protein-coupled receptors are the most prolific initiators of cell signaling pathways. The largest class of drug targets, they are also, unfortunately, the most intractable to drug development. Three research papers shows how combining different techniques -- crystallography, hydrogen exchange, and electron microscopy -- can shed new light on the nuances of GPCR signaling and how this kind of integrated approach could help identify new drug targets.

Back To School: Big Pharmas Test New Models For Tapping Academia

Pfizer's ambitious tie-ups with multiple research institutions across several cities is but the latest model of academic-industry collaboration, highlighting pharma's ongoing hunger for fresh approaches to drug discovery.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel